Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?

  • Song, Tao (Department of Radiation Oncology, The First Clinical College of Wenzhou Medical University, Hangzhou Cancer Hospital) ;
  • Yu, Wei (Department of Radiation Oncology, The First Clinical College of Wenzhou Medical University, Hangzhou Cancer Hospital) ;
  • Wu, Shi-Xiu (Department of Radiation Oncology, Hangzhou Cancer Hospital)
  • Published : 2014.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great advantages over traditional treatment strategies in patients with non-small cell lung cancer (NSCLC), but unfortunately we have to face the situation that most patients still fail to respond in the long term despite initially good control. Up to now, the mechanism of acquired resistance to EGFR-TKIs has not been fully clarified. Herein, we sought to compile the available clinical reports in the hope to better understanding the subsequent treatment choices, particularly on whether restoring after a drug holiday or switching to another EGFR-TKI is the better option after failure of one kind of EGFR-TKI.

Keywords

References

  1. Asahina H, Oizumi S, Inoue A, et al (2010). Phase II study of gefitinib readministration in patients with advanced nonsmall cell lung cancer and previous response to gefitinib. Oncology, 79, 423-9. https://doi.org/10.1159/000326488
  2. Asami K, Kawahara M, Atagi S, Kawaguchi T and Okishio K (2011). Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer, 73, 211-6. https://doi.org/10.1016/j.lungcan.2010.12.014
  3. Balak MN, Gong Y, Riely GJ, et al (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res, 12, 6494-501. https://doi.org/10.1158/1078-0432.CCR-06-1570
  4. Bean J, Brennan C, Shih JY, et al (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Nat Acad Sci, 104, 20932-7. https://doi.org/10.1073/pnas.0710370104
  5. Becker A, Crombag L, Heideman DA, et al (2011). Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer, 47, 2603-6. https://doi.org/10.1016/j.ejca.2011.06.046
  6. Campbell A, Reckamp K, Camidge D, et al (2010). PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol, 28, 7596.
  7. Chaft JE, Oxnard GR, Sima CS, et al (2011). Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res, 17, 6298-303. https://doi.org/10.1158/1078-0432.CCR-11-1468
  8. Chang JW, Chou CL, Huang SF, et al (2007). Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer, 58, 414-7. https://doi.org/10.1016/j.lungcan.2007.05.018
  9. Cho BC, Im CK, Park MS, et al (2007). Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol, 25, 2528-33. https://doi.org/10.1200/JCO.2006.10.4166
  10. Costa DB, Nguyen KS, Cho BC, et al (2008). Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res, 14, 7060-7. https://doi.org/10.1158/1078-0432.CCR-08-1455
  11. Downey RJ, Ng KK, Kris MG, et al (2002). A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer, 38, 193-7. https://doi.org/10.1016/S0169-5002(02)00183-6
  12. Faehling M, Eckert R, Kamp T, et al (2013). EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. Lung Cancer, 80, 306-12. https://doi.org/10.1016/j.lungcan.2013.02.010
  13. Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 29, 2866-74. https://doi.org/10.1200/JCO.2010.33.4235
  14. Garfield DH (2005). Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J Clin Oncol, 23, 7738-40. https://doi.org/10.1200/JCO.2005.02.4471
  15. Giaccone G and Wang Y (2011). Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev, 37, 456-64.
  16. Goto Y, Sekine I, Tanioka M, et al (2012). Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. Invest New Drugs, 30, 1548-56. https://doi.org/10.1007/s10637-011-9715-4
  17. Gridelli C, Maione P, Galetta D, et al (2007). Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol, 2, 758-61. https://doi.org/10.1097/JTO.0b013e3180cc25b0
  18. Grossi F, Rijavec E, Dal Bello MG, et al (2012). The administration of gefitinib in patients with advanced nonsmall-cell lung cancer after the failure of erlotinib. Cancer Chemother Pharmacol, 69, 1407-12. https://doi.org/10.1007/s00280-012-1848-4
  19. Guo R, Chen X, Wang T, et al (2011). Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer, 11, 90. https://doi.org/10.1186/1471-2407-11-90
  20. Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
  21. Hata A, Katakami N, Yoshioka H, et al (2011). Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer, 74, 268-73. https://doi.org/10.1016/j.lungcan.2011.03.010
  22. Hirsh V, Cadranel J, Cong XJ, et al (2013). Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol, 8, 229-37. https://doi.org/10.1097/JTO.0b013e3182773fce
  23. Jackman D, Pao W, Riely GJ, et al (2010). Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol, 28, 357-60. https://doi.org/10.1200/JCO.2009.24.7049
  24. Jackman DM, Holmes AJ, Lindeman N, et al (2006). Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol, 24, 4517-20. https://doi.org/10.1200/JCO.2006.06.6126
  25. Janjigian Y, Groen H, Horn L, et al (2011). Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol, 29, abstr7525.
  26. Jensen SB, Pedersen AM, Vissink A, et al (2010). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer, 18, 1061-79. https://doi.org/10.1007/s00520-010-0837-6
  27. Kaira K, Naito T, Takahashi T, et al (2010). Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer, 68, 99-104. https://doi.org/10.1016/j.lungcan.2009.05.006
  28. Kim H, Kim Y, Oh S, et al (2008). Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation. J Clin Oncol, 26, 19072.
  29. Koizumi T, Agatsuma T, Ikegami K, et al (2012). Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Clin Lung Cancer, 13, 458-63. https://doi.org/10.1016/j.cllc.2012.01.006
  30. Kurata T, Tamura K, Kaneda H, et al (2004). Effect of retreatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol, 15, 173-4. https://doi.org/10.1093/annonc/mdh006
  31. Laack E, Sauter G and Bokemeyer C (2010). Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. Lung Cancer, 69, 259-64. https://doi.org/10.1016/j.lungcan.2010.05.015
  32. Lee DH, Kim SW, Suh C, et al (2008). Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol, 19, 2039-42. https://doi.org/10.1093/annonc/mdn423
  33. Li XD, Geng YT, Wu CP, et al (2010). Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie, 33, 466-9. https://doi.org/10.1159/000319109
  34. Luo D, Huang M, Zhang X, et al (2012). Salvage treatment with erlotinib after gefitinib failure in advanced non-smallcell lung cancer patients with poor performance status: A matched-pair case-control study. Thoracic Cancer, 3, 27-33. https://doi.org/10.1111/j.1759-7714.2011.00087.x
  35. Marquez-Medina D, Chachoua A, Martin-Marco A, et al (2013). Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers? Clin Transl Oncol.
  36. Miller V, Hirsh V and Cadranal J (2010). Subgroup analysis of LUX-Lung 1: a randomized phase III trial of afatinib (BIBW 2992)+ best supportive care (BSC) versus placebo+ BSC in patients failing 1-2 lines of chemotherapy and erlotinib or gefitinib [abstract LBPL3]. J Thorac Oncol, 5, S557. https://doi.org/10.1097/JTO.0b013e3182016287
  37. Miller VA, Hirsh V, Cadranel J, et al (2012). Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 13, 528-38. https://doi.org/10.1016/S1470-2045(12)70087-6
  38. Nguyen KS and Neal JW (2012). First-line treatment of EGFRmutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics, 6, 337-45.
  39. Oh IJ, Ban HJ, Kim KS and Kim YC (2012). Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer, 77, 121-7. https://doi.org/10.1016/j.lungcan.2012.01.012
  40. Ohsaki Y, Tanno S, Fujita Y, et al (2000). Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep, 7, 603-7.
  41. Pallis AG and Syrigos KN (2013). Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer, 80, 120-30. https://doi.org/10.1016/j.lungcan.2012.12.025
  42. Park K, Heo D, Cho B, et al, 2010. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study, J Clin Oncol (Meeting Abstracts), pp. 7599.
  43. Park K, Tsai CM, Ahn MJ, et al (2012). ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA.
  44. Pfannschmidt J, Schlolaut B, Muley T, Hoffmann H and Dienemann H (2005). Adrenalectomy for solitary adrenal metastases from non-small cell lung cancer. Lung Cancer, 49, 203-7. https://doi.org/10.1016/j.lungcan.2005.02.012
  45. Riely GJ, Kris MG, Zhao B, et al (2007). Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res, 13, 5150-5. https://doi.org/10.1158/1078-0432.CCR-07-0560
  46. Rosell R, Gervais R, Vergnenegre A, et al (2011). Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol, 29, 7503.
  47. Saito H, Murakami S, Kondo T, et al (2012). Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months. Onkologie, 35, 18-22.
  48. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  49. Sequist LV, Bell DW, Lynch TJ and Haber DA (2007). Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol, 25, 587-95. https://doi.org/10.1200/JCO.2006.07.3585
  50. Sequist LV, Besse B, Lynch TJ, et al (2010). Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small cell lung cancer. J Clin Oncol, 28, 3076-83. https://doi.org/10.1200/JCO.2009.27.9414
  51. Sequist LV, Martins RG, Spigel D, et al (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol, 26, 2442-9. https://doi.org/10.1200/JCO.2007.14.8494
  52. Sequist LV, Waltman BA, Dias-Santagata D, et al (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 75ra26.
  53. Shaw AT, Kim DW, Nakagawa K, et al (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med.
  54. Shih YN, Liou JL, Jiang WC, et al (2007). Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment: P3-150. Journal of Thoracic Oncology, 2, S743.
  55. Shoji F, Kawano D, Ito K, et al (2011). Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case. Surg Today, 41, 255-7. https://doi.org/10.1007/s00595-009-4259-3
  56. Shukuya T, Takahashi T, Naito T, et al (2011). Continuous EGFRTKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer, 74, 457-61. https://doi.org/10.1016/j.lungcan.2011.04.007
  57. Sim SH, Han SW, Oh DY, et al (2009). Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer, 65, 204-7. https://doi.org/10.1016/j.lungcan.2008.11.006
  58. Song ZB, Yu YF, Chen ZW and Lu S (2011). Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. Chin Med J (Engl), 124, 2279-83.
  59. Tomizawa Y, Fujita Y, Tamura A, et al (2010). Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer, 68, 269-72. https://doi.org/10.1016/j.lungcan.2009.06.025
  60. Vasile E, Tibaldi C, Chella A and Falcone A (2008). Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol, 3, 912-4. https://doi.org/10.1097/JTO.0b013e318180275e
  61. Viswanathan A, Pillot G and Govindan R (2005). Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 50, 417-8. https://doi.org/10.1016/j.lungcan.2005.07.004
  62. Volm M, Rittgen W and Drings P (1998). Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer, 77, 663-9. https://doi.org/10.1038/bjc.1998.106
  63. Voltolini L, Rapicetta C, Luzzi L, et al (2010). Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg, 37, 1198-204. https://doi.org/10.1016/j.ejcts.2009.11.025
  64. Walther JC, Khorshid M, Gaya A and Plowman PN (2006). Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash. Clin Oncol (R Coll Radiol), 18, 637-9. https://doi.org/10.1016/j.clon.2006.07.002
  65. Watanabe S, Tanaka J, Ota T, et al (2011). Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 11, 1. https://doi.org/10.1186/1471-2407-11-1
  66. Weickhardt AJ, Scheier B, Burke JM, et al (2012). Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted nonsmall-cell lung cancer. J Thorac Oncol, 7, 1807-14. https://doi.org/10.1097/JTO.0b013e3182745948
  67. Wong AS, Soong R, Seah SB, et al (2008). Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol, 3, 400-4. https://doi.org/10.1097/JTO.0b013e318168c801
  68. Wong MK, Lo AI, Lam B, et al (2010). Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol, 65, 1023-8. https://doi.org/10.1007/s00280-009-1107-5
  69. Yano S, Nakataki E, Ohtsuka S, et al (2005). Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res, 15, 107-11.
  70. Yano T, Haro A, Yoshida T, et al (2010). Prognostic impact of local treatment against postoperative oligometastases in nonsmall cell lung cancer. J Surg Oncol, 102, 852-5. https://doi.org/10.1002/jso.21750
  71. Yokouchi H, Yamazaki K, Kinoshita I, et al (2007). Clinical benefit of readministration of gefitinib for initial gefitinibresponders with non-small cell lung cancer. BMC Cancer, 7, 51. https://doi.org/10.1186/1471-2407-7-51
  72. Yoshimoto A, Inuzuka K, Kita T, Kawashima A, Kasahara K (2007). Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci, 333, 221-5. https://doi.org/10.1097/MAJ.0b013e31803b8acb
  73. Yu HA, Sima CS, Huang J, et al (2013). Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol, 8, 346-51. https://doi.org/10.1097/JTO.0b013e31827e1f83
  74. Zhou C, Wu Y-L, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The lancet oncology, 12, 735-742. https://doi.org/10.1016/S1470-2045(11)70184-X
  75. Zhou ZT, Xu XH, Wei Q, et al (2009). Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol, 64, 1123-7. https://doi.org/10.1007/s00280-009-0973-1

Cited by

  1. Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147
  2. Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2915
  3. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy vol.18, pp.1, 2017, https://doi.org/10.1186/s40360-017-0130-0
  4. The prognosis analysis of epidermal growth factor receptor tyrosine kinase inhibitor targeted treatment combined with chemotherapy in smokers with non-small cell lung cancer pp.07302312, 2018, https://doi.org/10.1002/jcb.27811